Latest news
Loading news…
Ultimovacs
ClosedOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 LowHeat score — how much recent activity & attention the company has (web traffic, news, hiring). Oslo, Norway Founded 2011 11-50 employees For Profit
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.
Ultimovacs was acquired by Zelluna Immunotherapy in 2024.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
11
Patents
8
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Delisted
- Ticker
- ULTI
- Exchange
- OSE - Oslo Stock Exchange
- IPO date
- Jun 3, 2019
- Raised at IPO
- $42M
- Delisted
- Mar 3, 2025
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 5
- Patents granted
- 8
- Trademarks
- 0
- Top patent class
- Organic Chemistry
- IT spend
- $323K
Company Info
- Founded
- 2011
- Employees
- 11-50
- Operating status
- Closed
- Company type
- For Profit
- Org types
- company
- Founders
- 1
- News articles
- 36
- HQ
- Oslo, Norway
- Region
- Nordic Countries, Scandinavia, Europe, Middle East, and Africa (EMEA)
- Exit date
- Jun 3, 2019
- Closed
- Mar 3, 2025
Signals & Scores
- Heat score
- Low
- Trend (7d)
- 0
- Trend (30d)
- -0.2
- Trend (90d)
- -0.1
- Last leadership hire
- Dec 17, 2024
11
professional contacts at Ultimovacs
Contact execs at Ultimovacs →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Ultimovacs
Loading news…
FAQs about Ultimovacs
People who checked this page also checked these
Browse the full Acquirezy directory.